EURAND NAMES EUROPEAN DIRECTOR OF BUSINESS DEVELOPMENT

MILAN, ITALY - Eurand, a specialty pharmaceutical company, today announced the appointment of Mr. Steve Ellul to the position of Director of Business Development for Eurand's European business.

"We are delighted to welcome Steve to the Eurand team. With more than 15 years of experience of Business Development in the pharmaceutical industry, we believe that he will be an important driver of our future growth," said Gearoid Faherty, Chief Executive Officer of Eurand.

Prior to joining Eurand, Steve worked as Director, European Licensing for Elan Corporation Ltd. based in Dublin, Ireland. At Elan, Steve contributed to global strategy development for the company's drug delivery unit and was responsible for its implementation in Europe. Steve began his career as a medical representative in the UK with Glaxo Pharmaceuticals. He subsequently managed the UK sales group for life science company, ImmunoGen International before joining PPL Therapeutics as Business Development Manager. There his responsibilities included securing partnerships for the company's internally generated product pipeline, its transgenic manufacturing technology as well as in-licensing complimentary technologies. Steve has a B.Sc in Chemistry from the University of Wales.

Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug delivery technologies. The Company specializes in bioavailability enhancement of poorly soluble drugs, modified release and taste masking and is currently developing a pipeline of products based on its proprietary drug delivery technologies. Eurand also works with many of the world's leading pharmaceutical and biotechnology companies to develop enhanced forms of their existing products and their compounds in development. Eurand's principal operating offices are in Milan, Italy, while US business is directed form Eurand, Inc. in Vandalia, Ohio, USA. The Company has research, development and manufacturing facilities in Italy, the United States and France.